July 20, 2016
Biotheranostics Appoints Industry Veteran Don Hardison to Board of Directors
FOR IMMEDIATE RELEASE…July 20, 2016…SAN DIEGO…Biotheranostics, Inc., today announced that Don Hardison has been appointed to its Board of Directors. Hardison will help steer the company as it continues its exceptional commercial growth driven by molecular diagnostic tests that provide meaningful, personalized information to improve cancer diagnosis and treatment.
Hardison brings more than 30 years of leadership experience at such companies as EXACT Sciences, Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham Corp. He has a proven track record in sales, marketing, business development, and laboratory management. Most recently, Hardison was President, CEO, and Director of Good Start Genetics, Inc. He served in a similar capacity at EXACT Sciences from 2000 to 2007.
“We are pleased that Don has accepted our invitation to join the Biotheranostics Board,” said Nicolas Barthelemy, President and Chief Executive Officer. “Don’s extensive experience in diagnostic laboratory management and business leadership will be invaluable as we continue to rapidly grow our business and evolve our proprietary tests to address key unmet needs for the hundreds of thousands of patients annually diagnosed with early-stage breast cancer and metastatic cancer.”
“I am excited to work with Nicolas, his team, and the Biotheranostics board as they continue their important mission to build a valuable company through developing and providing accurate, actionable, molecular-based information for physicians in order to better diagnose disease, and to ultimately provide the best individual treatment for cancer patients,” Hardison said.
Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its CancerTYPE ID® is the most rigorously validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens with the goal of improving patient outcomes. Biotheranostics operates a CLIA-certified, CAP-accredited diagnostic laboratory in San Diego. Learn more at biotheranostics.com.